Evaluation of the COBAS hepatitis C virus (HCV) TaqMan analyte-specific reagent assay and comparison to the COBAS amplicor HCV monitor V2.0 and versant HCV bDNA 3.0 assays

Journal of Clinical Microbiology

Volumn 43, Issue 5, 2005, Pages 2133-2140

  Konnick, Eric Q ^a   Williams, Sheri M ^a   Ashwood, Edward R ^a,b   Hillyard, David R ^a,b  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA B; REAGENT;

ANTIGEN SPECIFICITY; ARTICLE; ASSAY; CHEMOLUMINESCENCE; COBAS HEPATITIS C VIRUS TAQMAN ANALYTE SPECIFIC REAGENT ASSAY; CONTAMINATION; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; INFECTION CONTROL; PRIORITY JOURNAL; REGRESSION ANALYSIS; SAMPLING; VIRUS DETECTION; VIRUS GENOME;

DNA, VIRAL; GENOTYPE; HEPACIVIRUS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY;

HEPATITIS C VIRUS;

EID: 18544379953     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.43.5.2133-2140.2005     Document Type: Article

References (16)

1. Barbeau, J. M., J. Goforth, A. M. Caliendo, and F. S. Nolle. 2004. Performance characteristics of a quantitative TaqMan hepatitis C virus RNA analyte-specific reagent. J. Clin. Microbiol. 42:3739-3746.
2. Dufour, D. R., J. A. Lott, F. S. Nolte, D. R. Gretch, R. S. Koff, and L. B. Seeff. 2000. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin. Chem. 46:2027-2049.
3. Elbeik, T., J. Surtihadi, M. Destree, J. Gorlin, M. Holodniy, S. A. Jortani, K. Kuramoto, V. Ng, R. Valdes, Jr., A. Valsamakis, and N. A. Terrault. 2004. Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA). J. Clin. Microbiol. 42:563-569.
4. Forman, M. S., and A. Valsamakis. 2004. Verification of an assay for quantification of hepatitis C virus RNA by use of an analyte-specific reagent and two different extraction methods. J. Clin. Microbiol. 42:3581-3588.
5. Fried, M. W., M. L. Shiffman, K. R. Reddy, C. Smith, G. Marinos, F. L. Goncales, Jr., D. Haussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, and J. Yu. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
6. Germer, J. J., P. J. Heimgartner, D. M. Ilstrup, W. S. Harmsen, G. D. Jenkins, and R. Patel. 2002. Comparative evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONITOR version 2.0 assays for quantification of hepatitis C virus RNA in serum. J. Clin. Microbiol. 40:495-500.
7. Cleaves, C. A., J. Welle, M. Campbell, T. Elbeik, V. Ng, P. E. Taylor, K. Kuramoto, S. Aceituno, E. Lewalski, B. Joppa, L. Sawyer, C. Schaper, D. McNairn, and T. Quinn. 2002. Multicenter evaluation of the Bayer VERSANT HIV-1 RNA 3.0 assay: analytical and clinical performance. J. Clin. Virol. 25:205-216.
8. Hadziyannis, E., A. Hadziyannis, B. Yen-Lieberman, M. L. Kiwi, S. Hodnick. F. Spanou, C. Starkey, and Z. M. Younossi. 2001. Hepatitis C virus RNA assays: a comparison of SuperQuant and Monitor. J. Clin. Gastroenterol. 33:45-48.
9. Konnick, E. Q., M. Erali, E. R. Ashwood, and D. R. Hillyard. 2002. Performance characteristics of the COBAS Amplicor hepatitis C virus (HCV) Monitor, version 2.0, international unit assay and the National Genetics Institute HCV Superquant assay. J. Clin. Microbiol. 40:768-773.
10. Martinot-Peignoux, M., N. Boyer, V. Le Breton, G. Le Guludec, C. Castelnau, R. Akremi, and P. Marcellin. 2000. A new step toward standardization of serum hepatitis C virus-RNA quantification in patients with chronic hepatitis C. Hepatology 31:726-729.
11. Murphy, D. G., L. Cote, M. Fauvel, P. Rene, and J. Vincelette. 2000. Multicenter comparison of Roche COBAS AMPLICOR MONITOR version 1.5, Organon Teknika NucliSens QT with Extractor, and Bayer Quantiplex version 3.0 for quantification of human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 38:4034-4041.
12. Pawlotsky, J. M. 2002. Use and interpretation of virological tests for hepatitis C. Hepatology 36:S65-S73.
13. Pisani, G., K. Cristiano, M. Wirz, G. M. Bisso, and G. Gentili. 2002. Over-estimation of the hepatitis C virus RNA content of reference preparations by the AMPLICOR HCV Monitor test, version 2.0. J. Clin. Microbiol. 40:4765-4767.
14. Pradat, P., P. Chossegros, F. Bailly, P. Pontisso, G. Saracco, S. Sauleda, M. Thursz, H. Tillmann, H. Vlassopoulou, A. Alberti, J. H. Braconier, J. I. Esteban, S. Hadziyannis, M. Manns, M. Rizzetto, H. C. Thomas, and C. Trepo. 2000. Comparison between three quantitative assays in patients with chronic hepatitis C and their relevance in the prediction of response to therapy. J. Viral Hepat. 7:203-210.
15. Sarrazin, C., D. A. Hendricks, F. Sedarati, and S. Zeuzem. 2001. Assessment, by transcription-mediated amplification, of virologic response in patients with chronic hepatitis C virus treated with peginterferon alpha-2a. J. Clin. Microbiol. 39:2850-2855.
16. Veillon, P., C. Payan, G. Picchio, M. Maniez-Montreuil, P. Guntz, and F. Lunel. 2003. Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and Amplicor Monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy. J. Clin. Microbiol. 41:3212-3220.